How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

New Long COVID Research Identifies Biomarkers, Immune Networks, and Cognitive Therapy

NFID Finds Nearly Half of US Adults Admit to Not Washing Their Hands at Key Moments

Prompts in Computerized Order Entry Improve Antimicrobial Treatment for Skin, Soft Tissue Infections

Top 5 Infectious Disease News Stories Week of April 26-May 3

FDA Asks for More Data for Moderna’s Influenza COVID-19 Combination Vaccine

Dose Optimization as a Strategy to Improve Clinical Outcomes and Suppress Antimicrobial Resistance

NIH Launches Generation Gold Standard Universal Vaccine Initiative

Responding to the Needs of an Aging Population

Warmer Winters Are Fueling a Surge in Tick-Borne Illnesses

New Microarray Platform Aims to Improve Tick-Borne Disease Diagnosis

Schedule an Appointment

Quick Links

Patient Forms

Contact Us